Skip to main content

Table 1 Patients characteristics

From: Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

Characteristics

Number of patients

Percentage

Age

  

≤ 60

12

38.7

> 60

19

61.3

Gender

  

Male

23

74.2

Female

8

25.8

ECOG PS

  

0-1

27

87.1

2-4

4

12.9

B symptom

  

Absent

14

48.3

Present

15

51.7

Bulky disease

  

Absent

21

67.7

Present

10

32.3

LDH

  

Normal

4

12.9

Elevated

27

87.1

Primary site of adrenal gland

  

Unilateral

12

38.7

Bilateral

19

61.3

Adrenal insufficiency

  

Absent

10

62.5

Present

6

37.5

Ann Arbor stage

  

IE, IIE

5

16.1

IIIE, IV

26

83.9

Number of extranodal sites

  

0-1

7

22.6

2 or more

24

77.4

Ki-67 LI

  

> 80%

11

57.9

≤ 80%

8

42.1

IPI

  

Low/Low-intermediate

8

25.8

High-intermediate/High

23

74.2

  1. ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; Ki-67 LI, Ki-67 labeling Index; IPI, International Prognostic Index.